Presto! Wall Street ma­gi­cian Vivek Ra­maswamy has an­oth­er in­stant biotech IPO to sell you

A pair of biotechs are look­ing to raise more than $250 mil­lion through IPOs, slip­ping in­to the short queue on the last work­ing day of Q3. One is from a Bermu­da-based ad­ven­tur­er with a knack for shak­ing loose cheap, late-stage as­sets from phar­ma’s R&D shelves and the oth­er is a ven­ture-backed play­er with plans to carve out a share of a block­buster fran­chise.

The first is My­ovant Sci­ences, an­oth­er in­stant-mix biotech from the 30-year-old for­mer hedge fund man­ag­er Vivek Ra­maswamy. This time, the young fi­nancier has con­jured a com­pa­ny with a re­spect­ed sci­en­tist at the helm and for­mer HHS Sec­re­tary Kath­leen Se­be­lius on the board.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA